Open AccessA Unique Three-Way Variant Philadelphia Chromosome t(6;9;22)(p21.3;q34;q11.2) in a Newly Diagnosed Patient with Chronic Myeloid Leukemia Responded to Flumatinib
Author(s) -
Lili Chen,
Junling Zhang,
Na Yang,
Ningping Tan,
Di Meng,
Fei Zhang,
Yongfeng Qi,
Guangqi Wu,
Zhenyu Li
Publication year - 2022
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s377342
Subject(s) - chromosomal translocation , myeloid leukemia , leukocytosis , philadelphia chromosome , karyotype , medicine , cancer research , chromosome , gastroenterology , oncology , biology , genetics , gene
Chronic myeloid leukaemia (CML) is a clonal malignant disorder of a pluripotent hematopoetic stem cell characterized by the presence of Philadelphia (Ph) chromosome in more than 90% of patients. However, about 5-10% of CML patients show a variant Ph translocation, involving one or more chromosomes in addition to 9 and 22. The treatment and prognostic impact of such additional abnormalities is not known. Herein, we report a unique case of a three-way translocation variant in CML and responded to flumatinib.